10x Genomics, Inc. Class A Common Stock (TXG) Financial Statements
Historical financial data — 27 statements covering FY2019–FY2025
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integr...
10x Genomics, Inc. Class A Common Stock's revenue increased 5.2% year over year, from $610.8M to $642.8M.
Net income increased 76.2% over the same period, from $-182.6M to $-43.5M.
Over the 6-year period from FY2019 to FY2025, revenue grew by 161% in total.
Operating cash flow grew 1941.6% to $136.1M.
10x Genomics, Inc. Class A Common Stock maintains a negative net profit margin of -6.8%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $153.1M+8.6% | $-37.9M | $104.2M | $-41.7M | $7.5M | $929.7M | N/A | $724.1M |
| Q3 FY2024 | $151.7M-0.9% | $-35.8M | $106.4M | $-41.5M | $21.6M | $937.8M | N/A | $722.8M |
| Q4 FY2024 | $165.0M+8.8% | $-49.0M | $111.0M | $-49.8M | $-6.7M | $918.6M | N/A | $710.1M |
| Q1 FY2025 | $154.9M-6.1% | $-34.4M | $105.4M | $-39.3M | $34.4M | $903.4M | N/A | $706.9M |
| Q2 FY2025 | $172.9M+11.6% | $34.5M | $125.1M | $30.1M | $17.7M | $980.0M | N/A | $773.3M |
| Q3 FY2025 | $149.0M-13.8% | $-27.5M | $100.3M | $-32.2M | $43.2M | $1.03B | N/A | $785.1M |
| Q4 FY2025 | $166.0M+11.4% | $-16.3M | $113.0M | $-19.5M | $40.8M | $1.04B | N/A | $796.3M |
| Q1 FY2026 | $150.8M-9.1% | $-13.5M | $106.2M | $-17.0M | $26.1M | $1.02B | N/A | $814.3M |
Balance Sheet Summary (Latest Period)
10x Genomics, Inc. Class A Common Stock (TXG) Financial Statements & Revenue History
10x Genomics, Inc. Class A Common Stock (TXG) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry trading at $85.50 with a market capitalization of $11. This page provides 27 historical financial statements for 10x Genomics, Inc. Class A Common Stock, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, 10x Genomics, Inc. Class A Common Stock reported revenue of $643 million, representing 5.2% year-over-year growth. The net profit margin of -6.8% indicates the company is currently unprofitable..
TXG Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows 10x Genomics, Inc. Class A Common Stock's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether TXG is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track TXG's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently 10x Genomics, Inc. Class A Common Stock converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of TXG's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use TXG Financial Data
Investors use 10x Genomics, Inc. Class A Common Stock's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare TXG's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how TXG's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View TXG's financial health score, earnings, and pre-market pricing.
Financial data is sourced from 10x Genomics, Inc. Class A Common Stock's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.TXG trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.